{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:11:21Z","timestamp":1783030281752,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":872,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbmt.2020.09.021","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T08:07:29Z","timestamp":1601021249000},"page":"57.e1-57.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma"],"prefix":"10.1016","volume":"27","author":[{"given":"Sherilyn A.","family":"Tuazon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor A.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela C.","family":"Matesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally J.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.09.021_bib0001","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0002","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0003","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0004","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0005","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0006","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0007","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0008","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0009","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0010","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0011","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":"Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"27","author":"Winter","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0012","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","article-title":"Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab","volume":"112","author":"Gopal","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0013","first-page":"107","article-title":"Expression of leukocyte common antigen (CD45) on various human leukemia\/lymphoma cell lines","volume":"40","author":"Nakano","year":"1990","journal-title":"Acta Pathol Jpn"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0014","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/1078-0432.CCR-19-1567","article-title":"Phase I study of a CD45-targeted antibody-radionuclide conjugate for high-risk lymphoma","volume":"25","author":"Cassaday","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.108.057331","article-title":"MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan","volume":"50","author":"Fisher","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0016","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/sim.903","article-title":"An evaluation of phase I clinical trial designs in the continuous dose-response setting","volume":"20","author":"Storer","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0017","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.1989.7.9.1288","article-title":"Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma","volume":"7","author":"Bearman","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0018","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0019","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0014-2964(81)90058-X","article-title":"High dose chemotherapy and autologous bone marrow transplantation in acute leukemias, malignant lymphomas and solid tumors: a study of 23 patients","volume":"17","author":"Gorin","year":"1981","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0020","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2019.229492","article-title":"Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed\/refractory leukemia or myelodysplasia","volume":"105","author":"Vo","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0021","article-title":"(90)Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma","author":"Tuazon","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0022","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0023","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/ejh.12775","article-title":"Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan","volume":"97","author":"Andrade-Campos","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0024","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1038\/s41375-020-0798-9","article-title":"Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study","volume":"34","author":"Di","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0027","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0028","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0029","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2020.09.021_bib0030","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120306157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120306157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:35:04Z","timestamp":1761089704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120306157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1083879120306157"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}